Veracyte Announces Data From Five Studies Validating the Next-Generation Afirma Genomic Sequencing Classifier to Be Presented at ATA 2017 Annual Meeting
"We believe the results of these studies highlight the Afirma GSC's
unique ability to provide physicians with answers, including answers to
the most challenging biological questions, as they evaluate patients for
thyroid cancer," said
Data from two studies evaluating the Afirma GSC's performance in two of the most challenging thyroid biologies will be shared as oral presentations at the ATA meeting:
Title: |
Development and Validation of Classifiers to Enhance the Afirma Genomic Sequencing Classifier Performance Among Hürthle Cell Specimens (Short Call Oral Abstract #6) |
|||
Presenter: |
|
|||
Date/Time: |
|
|||
Location: |
|
Title: |
Clinical Validation of the Afirma Genomic Sequencing Classifier for Medullary Thyroid Cancer (Oral Abstract #29) | |||
Presenter: |
|
|||
Date/Time: |
|
|||
Location: |
|
|||
The following abstracts will be presented as posters:
Title: |
Clinical Validation of the Afirma Genomic Sequencing BRAF V600E Classifier (Poster 167) | |||
Presenter: |
|
|||
Date/Time: |
|
|||
Location: |
|
Title: |
Clinical Validation of the Afirma Genomic Sequencing Parathyroid Classifier (Poster 168) | |||
Presenter: |
|
|||
Date/Time: |
|
|||
Location: |
|
Title: |
Analytical Performance of Afirma GSC: A Genomic Sequencing
Classifier for Cytology-Indeterminate Thyroid Nodule FNA Specimens
( |
|||
Presenter: |
Zhanzhi Hu, Ph.D., |
|||
Date/Time: |
|
|||
Location: |
|
|||
* All Pacific Time
About Afirma
The Afirma Genomic Sequencing Classifier is the next-generation version
of the Afirma Gene Expression Classifier, and is used to identify
patients with benign thyroid nodules among those with indeterminate
cytopathology results in order to preserve the thyroid. Each year in
About Veracyte
Cautionary Note Regarding Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "expect," "believe," "should," "may," "will" and similar references to future periods. Examples of forward-looking statements include, among others, our belief that our Afirma GSC's ability to further reduce unnecessary surgeries in thyroid cancer diagnosis while providing physicians information to enable more appropriate treatment when suspicious nodules are identified, our beliefs with respect to the results of the studies, including Afirma GSC's ability to provide answers to the most challenging biological questions in evaluating patients, our commitment to developing extensive clinical evidence required to generate confidence in our products, and the applicability of clinical results to actual outcomes. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, anticipated events and trends, the economy and other future conditions. Forward-looking statements involve risks and uncertainties, which could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: the applicability of clinical results to actual outcomes; laws and regulations applicable to our business, including potential regulation by the Food and Drug Administration or other regulatory bodies; the ability of our products to change treatment decisions and reduce unnecessary surgeries; the occurrence and outcomes of clinical studies; the timing and publication of clinical study results; and other risks set forth in the company's filings with the Securities and Exchange Commission, including the risks set forth in the company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2017. These forward-looking statements speak only as of the date hereof and Veracyte specifically disclaims any obligation to update these forward-looking statements.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171005005469/en/
Media:
tracy.morris@veracyte.com
or
Investors:
jackie@veracyte.com
Source:
News Provided by Acquire Media